H.C. Wainwright downgraded Cyclo Therapeutics (CYTH) to Neutral from Buy with a price target of 95c, down from $3, after the company entered into a definitive merger agreement with Rafael Holdings (RFL), which has agreed to acquire the company for 95c per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTH:
- Cyclo Therapeutics’ Merger and Financial Arrangements with Rafael Holdings
- Cyclo Therapeutics reports Q2 net loss approximately $6M
- CYTH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cyclo Therapeutics granted patent by European Patent Office
- One new option listing and eighteen option delistings on July 22nd